COMA
MCID: OCL069
MIFTS: 51

Ocular Motor Apraxia (COMA)

Categories: Eye diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Ocular Motor Apraxia

MalaCards integrated aliases for Ocular Motor Apraxia:

Name: Ocular Motor Apraxia 56
Coma 56 52 53 42
Oculomotor Apraxia, Congenital, Cogan-Type 56 13
Oculomotor Apraxia, Cogan Type 56 58
Saccade Initiation Failure, Congenital 56
Saccade Initiation Failure Congenital 52
Oculomotor Apraxia, Cogan Type; Coma 56
Ocular Motor Apraxia, Cogan Type 58
Oculomotor Apraxia Cogan Type 52
Congenital Oculomotor Apraxia 52
Cogan's Syndrome Type 2 52
Oculomotor Apraxia 71
Comatose 71

Characteristics:

Orphanet epidemiological data:

58
ocular motor apraxia, cogan type
Inheritance: Autosomal recessive; Prevalence: <1/1000000 (Worldwide); Age of onset: Childhood;

OMIM:

56
Inheritance:
autosomal recessive

Miscellaneous:
ocular movement dysfunction improves with age


HPO:

31
ocular motor apraxia:
Inheritance autosomal recessive inheritance


Classifications:

Orphanet: 58  
Rare eye diseases


External Ids:

OMIM 56 257550
ICD10 32 R40.2
MESH via Orphanet 44 C537423
ICD10 via Orphanet 33 H51.8
UMLS via Orphanet 72 C0543874
Orphanet 58 ORPHA1125
MedGen 41 C0543874
SNOMED-CT via HPO 68 193662007 204958008 258211005
UMLS 71 C0009421 C3489733

Summaries for Ocular Motor Apraxia

NIH Rare Diseases : 52 Oculomotor apraxia Cogan type (COMA) is an eye condition characterized by a defect in side-to-side (horizontal) eye movements. Because of this, most patients with COMA have to turn their head in order to follow objects in side gaze. Typically, up-to-down (vertical) eye movements are unaffected. Symptoms usually improve throughout the childhood and teenage years. COMA can also be associated with mild developmental delay and speech difficulties. Individuals with COMA may also have kidney disorders and underdevelopment of the part of cerebellum that separates the left and right hemisphere of the brain (cerebellar vermis). When other symptoms occur, COMA may be a symptom of other disorders, such as nephronophthisis or Joubert syndrome . In many instances, the cause of COMA is not known; however, researchers suspect that it is inherited in an autosomal recessive inheritance pattern. Treatment for this condition is focused on managing the signs and symptoms in each individual.

MalaCards based summary : Ocular Motor Apraxia, also known as coma, is related to apraxia and oculomotor apraxia, and has symptoms including seizures, tremor and back pain. An important gene associated with Ocular Motor Apraxia is COMA (Cogan-Type Congential Oculomotor Apraxia). The drugs Clavulanate and Dobutamine have been mentioned in the context of this disorder. Affiliated tissues include brain, liver and eye, and related phenotypes are nephronophthisis and oculomotor apraxia

OMIM : 56 Congenital oculomotor apraxia, first reported by Cogan (1952), is characterized by (1) defective or absent horizontal voluntary eye movements, and (2) defective or absent horizontal ocular attraction movements. Oculomotor apraxia occurs in ataxia-telangiectasia (208900). Also see ataxia-oculomotor apraxia syndrome (208920; 606002). Oculomotor apraxia has been observed in the neuronopathic form of Gaucher disease (type III; 231000) (Erikson and Wahlberg, 1985; Gross-Tsur et al., 1989). (257550)

MedlinePlus : 42 A coma is a deep state of unconsciousness. An individual in a coma is alive but unable to move or respond to his or her environment. Coma may occur as a complication of an underlying illness, or as a result of injuries, such as brain injury. A coma rarely lasts more than 2 to 4 weeks. The outcome for coma depends on the cause, severity, and site of the damage. People may come out of a coma with physical, intellectual, and psychological problems. Some people may remain in a coma for years or even decades. For those people, the most common cause of death is infection, such as pneumonia. NIH: National Institute of Neurological Disorders and Stroke

NINDS : 53 A coma, sometimes also called persistent vegetative state, is a profound or deep state of unconsciousness. Persistent vegetative state is not brain-death. An individual in a state of coma is alive but unable to move or respond to his or her environment. Coma may occur as a complication of an underlying illness, or as a result of injuries, such as head trauma. Individuals in such a state have lost their thinking abilities and awareness of their surroundings, but retain non-cognitive function and normal sleep patterns. Even though those in a persistent vegetative state lose their higher brain functions, other key functions such as breathing and circulation remain relatively intact. Spontaneous movements may occur, and the eyes may open in response to external stimuli. Individuals may even occasionally grimace, cry, or laugh. Although individuals in a persistent vegetative state may appear somewhat normal, they do not speak and they are unable to respond to commands.

Related Diseases for Ocular Motor Apraxia

Diseases related to Ocular Motor Apraxia via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 856, show less)
# Related Disease Score Top Affiliating Genes
1 apraxia 30.5 NPHP1 APTX
2 oculomotor apraxia 28.7 NPHP1 COMA APTX
3 hypoglycemic coma 12.8
4 hepatic coma 12.6
5 basedow's coma 12.4
6 viral hepatitis 11.9
7 ataxia, early-onset, with oculomotor apraxia and hypoalbuminemia 11.9
8 joubert syndrome 1 11.7
9 persistent vegetative state 11.6
10 akinetic mutism 11.6
11 hepatic encephalopathy 11.5
12 traumatic brain injury 11.5
13 creutzfeldt-jakob disease 11.5
14 familial hemiplegic migraine 11.5
15 ornithine transcarbamylase deficiency, hyperammonemia due to 11.5
16 lysinuric protein intolerance 11.5
17 acyl-coa dehydrogenase, medium-chain, deficiency of 11.5
18 propionic acidemia 11.5
19 brain edema 11.4
20 wernicke-korsakoff syndrome 11.4
21 japanese encephalitis 11.4
22 central pontine myelinolysis 11.4
23 citrullinemia, classic 11.4
24 carbamoyl phosphate synthetase i deficiency, hyperammonemia due to 11.4
25 hyperinsulinemic hypoglycemia, familial, 2 11.4
26 carnitine deficiency, systemic primary 11.4
27 acute disseminated encephalomyelitis 11.4
28 anoxia 11.3
29 malaria 11.3
30 eclampsia 11.3
31 reye syndrome 11.3
32 insulinoma 11.3
33 hypoxia 11.3
34 hypophosphatemia 11.3
35 cerebral hypoxia 11.3
36 n-acetylglutamate synthase deficiency 11.3
37 hyperornithinemia-hyperammonemia-homocitrullinuria syndrome 11.3
38 maple syrup urine disease 11.3
39 diabetes mellitus, type i 11.3
40 urea cycle disorder 11.3
41 pre-eclampsia 11.3
42 alcohol use disorder 11.3
43 carnitine palmitoyltransferase i deficiency 11.2
44 adrenoleukodystrophy 11.2
45 autoimmune encephalitis 11.2
46 sleeping sickness 11.2
47 st. louis encephalitis 11.2
48 marchiafava bignami disease 11.2
49 new-onset refractory status epilepticus 11.2
50 sporadic hemiplegic migraine 11.2
51 3-hydroxy-3-methylglutaryl-coa lyase deficiency 11.2
52 isovaleric acidemia 11.2
53 holocarboxylase synthetase deficiency 11.2
54 citrullinemia, type ii, adult-onset 11.2
55 thiamine metabolism dysfunction syndrome 2 11.2
56 long-chain 3-hydroxyacyl-coa dehydrogenase deficiency 11.2
57 encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy, 1 11.2
58 la crosse encephalitis 11.2
59 alpha-methylacetoacetic aciduria 11.1
60 argininosuccinic aciduria 11.1
61 carnitine-acylcarnitine translocase deficiency 11.1
62 succinyl-coa:3-oxoacid-coa transferase deficiency 11.1
63 3-methylglutaconic aciduria, type i 11.1
64 glycine encephalopathy 11.1
65 2-methylbutyryl-coa dehydrogenase deficiency 11.1
66 encephalopathy, acute, infection-induced 4 11.1
67 combined malonic and methylmalonic aciduria 11.1
68 3-methylcrotonyl-coa carboxylase deficiency 11.1
69 eastern equine encephalitis 11.1
70 von economo's disease 11.1
71 biotin-thiamine-responsive basal ganglia disease 11.1
72 adenosylcobalamin deficiency 11.1
73 immune-mediated encephalomyelitis 11.1
74 korsakoff's amnesic syndrome 11.1
75 postinfectious encephalomyelitis 11.1
76 diabetes insipidus, neurohypophyseal 10.9
77 leigh syndrome, french canadian type 10.9
78 fructose intolerance, hereditary 10.9
79 3-hydroxyacyl-coa dehydrogenase deficiency 10.9
80 methylmalonic aciduria due to methylmalonyl-coa mutase deficiency 10.9
81 methylmalonyl-coa epimerase deficiency 10.9
82 biotinidase deficiency 10.9
83 gyrate atrophy of choroid and retina 10.9
84 pyruvate carboxylase deficiency 10.9
85 hemophagocytic lymphohistiocytosis, familial, 1 10.9
86 carnitine palmitoyltransferase ii deficiency, infantile 10.9
87 cerebellar ataxia, areflexia, pes cavus, optic atrophy, and sensorineural hearing loss 10.9
88 megalencephalic leukoencephalopathy with subcortical cysts 1 10.9
89 citrullinemia, type ii, neonatal-onset 10.9
90 acute hemorrhagic leukoencephalitis 10.9
91 mitochondrial trifunctional protein deficiency 10.9
92 colloid cysts of third ventricle 10.9
93 encephalopathy, acute, infection-induced 1 10.9
94 mitochondrial complex i deficiency, nuclear type 20 10.9
95 porphyria, acute hepatic 10.9
96 encephalopathy, acute, infection-induced 2 10.9
97 thiamine metabolism dysfunction syndrome 5 10.9
98 encephalopathy, acute, infection-induced 5 10.9
99 encephalopathy, acute, infection-induced 6 10.9
100 maple syrup urine disease, mild variant 10.9
101 lipoyltransferase 1 deficiency 10.9
102 encephalopathy, acute, infection-induced 7 10.9
103 encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy, 2 10.9
104 powassan encephalitis 10.9
105 nipah virus encephalitis 10.9
106 primary amebic meningoencephalitis 10.9
107 familial glucocorticoid deficiency 10.9
108 louping ill 10.9
109 gnathomiasis 10.9
110 leukostasis 10.9
111 methylmalonic acidemia 10.9
112 cholera 10.9
113 hepatitis d 10.9
114 west nile encephalitis 10.9
115 acute necrotizing encephalitis 10.9
116 progressive multifocal leukoencephalopathy 10.9
117 familial creutzfeld-jakob disease 10.9
118 carbonic anhydrase va deficiency 10.9
119 3-alpha hydroxyacyl-coa dehydrogenase deficiency 10.9
120 acute ackee fruit intoxication 10.9
121 baylisascaris infection 10.9
122 familiar or sporadic hemiplegic migraine 10.9
123 gnathostoma infection 10.9
124 mollaret meningitis 10.9
125 staphylococcal toxic shock syndrome 10.9
126 west nile virus encephalitis 10.9
127 acute necrotizing encephalopathy type 1 10.9
128 corticosterone methyloxidase deficiency 10.9
129 critical congenital heart disease 10.9
130 aids - neurological complications 10.9
131 extrapontine myelinolysis 10.9
132 hepatitis a 10.8
133 head injury 10.8
134 myxedema 10.8
135 cardiac arrest 10.7
136 hypoglycemia 10.7
137 moderate and severe traumatic brain injury 10.7
138 brain injury 10.7
139 ataxia and polyneuropathy, adult-onset 10.6
140 hypothyroidism 10.6
141 status epilepticus 10.6
142 diabetes mellitus, ketosis-prone 10.6
143 liver cirrhosis 10.6
144 hyperglycemia 10.5
145 diabetes mellitus 10.5
146 respiratory failure 10.5
147 intracranial hypertension 10.5
148 ataxia-telangiectasia 10.5
149 pathologic nystagmus 10.5
150 metabolic acidosis 10.5
151 acute liver failure 10.5
152 telangiectasis 10.4
153 carbonic anhydrase va deficiency, hyperammonemia due to 10.4
154 encephalopathy, progressive, early-onset, with episodic rhabdomyolysis 10.4
155 subacute delirium 10.4
156 encephalitis 10.4
157 pancreatitis 10.4
158 cogan syndrome 10.4
159 hypotonia 10.4
160 liver disease 10.4
161 astigmatism 10.3
162 acute kidney failure 10.3
163 kidney disease 10.3
164 migraine with or without aura 1 10.3
165 hypokalemia 10.3
166 acute pancreatitis 10.3
167 lactic acidosis 10.3
168 myoclonus 10.3
169 intracranial hypotension 10.3
170 quadriplegia 10.3
171 amnestic disorder 10.3
172 meningitis 10.3
173 headache 10.3
174 hydrocephalus 10.3
175 nephronophthisis 10.3
176 gaucher's disease 10.3
177 juvenile nephronophthisis 10.3
178 hemiplegia 10.2
179 diabetes insipidus 10.2
180 schizophrenia 10.2
181 48,xyyy 10.2
182 aphasia 10.2
183 locked-in syndrome 10.2
184 thyroiditis 10.2
185 thrombosis 10.2
186 meningoencephalitis 10.2
187 thyroid crisis 10.2
188 congestive heart failure 10.2
189 friedreich ataxia 10.2
190 gaucher disease, type i 10.2
191 nephronophthisis 1 10.2
192 yemenite deaf-blind hypopigmentation syndrome 10.2
193 cerebellar hypoplasia 10.2
194 cortical blindness 10.2
195 gm1 gangliosidosis 10.2
196 peripheral nervous system disease 10.2
197 neuropathy 10.2
198 gangliosidosis 10.2
199 neonatal hypoxic and ischemic brain injury 10.2
200 wernicke encephalopathy 10.2
201 hypopituitarism 10.2
202 spontaneous intracranial hypotension 10.2
203 varicose veins 10.1
204 graves disease 1 10.1
205 bacterial meningitis 10.1
206 hepatitis 10.1
207 adenoma 10.1
208 alcohol dependence 10.1
209 anisocoria 10.1
210 hyperthyroidism 10.1
211 tremor 10.1
212 stroke, ischemic 10.1
213 aortic dissection 10.1
214 portal hypertension 10.1
215 disseminated intravascular coagulation 10.1
216 cardiogenic shock 10.1
217 corpus callosum, agenesis of 10.1
218 ventricular fibrillation, paroxysmal familial, 1 10.0
219 anorexia nervosa 10.0
220 esophageal varix 10.0
221 rabies 10.0
222 adult respiratory distress syndrome 10.0
223 heart disease 10.0
224 hemopericardium 10.0
225 pericardial effusion 10.0
226 pancytopenia 10.0
227 diarrhea 10.0
228 neuroleptic malignant syndrome 10.0
229 mutism 10.0
230 uremia 10.0
231 pneumonia 10.0
232 viral encephalitis 10.0
233 cerebrovascular disease 10.0
234 cerebral atrophy 10.0
235 spasticity 10.0
236 syncope 10.0
237 cornelia de lange syndrome 1 10.0
238 hypercholesterolemia, familial, 1 10.0
239 lipomatosis, multiple 10.0
240 medulloblastoma 10.0
241 strabismus 10.0
242 takayasu arteritis 10.0
243 dandy-walker syndrome 10.0
244 sandhoff disease 10.0
245 tay-sachs disease 10.0
246 pelizaeus-merzbacher disease 10.0
247 kearns-sayre syndrome 10.0
248 epilepsy, idiopathic generalized 10.0
249 ataxia-telangiectasia-like disorder 1 10.0
250 alacrima, achalasia, and mental retardation syndrome 10.0
251 poretti-boltshauser syndrome 10.0
252 analbuminemia 10.0
253 dyskinetic cerebral palsy 10.0
254 cone dystrophy 10.0
255 autosomal recessive cerebellar ataxia 10.0
256 agraphia 10.0
257 pleomorphic lipoma 10.0
258 microphthalmia 10.0
259 microcephaly 10.0
260 cornelia de lange syndrome 10.0
261 visual epilepsy 10.0
262 vestibular nystagmus 10.0
263 autosomal dominant cerebellar ataxia 10.0
264 niemann-pick disease 10.0
265 communicating hydrocephalus 10.0
266 bardet-biedl syndrome 10.0
267 cerebral palsy 10.0
268 ankylosis 10.0
269 astrocytoma 10.0
270 myopathy 10.0
271 dysgraphia 10.0
272 dystonia 10.0
273 nervous system disease 10.0
274 neurofibromatosis 10.0
275 learning disability 10.0
276 mechanical strabismus 10.0
277 encephalopathy 10.0
278 infantile hypotonia 10.0
279 seizure disorder 10.0
280 spinocerebellar degeneration 10.0
281 spasmus nutans 10.0
282 cerebral arteriopathy, autosomal dominant, with subcortical infarcts and leukoencephalopathy, type 1 10.0
283 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.0
284 myeloma, multiple 10.0
285 anemia, x-linked, with or without neutropenia and/or platelet abnormalities 10.0
286 myocardial infarction 10.0
287 human immunodeficiency virus type 1 10.0
288 deficiency anemia 10.0
289 aspiration pneumonia 10.0
290 intracranial aneurysm 10.0
291 pulmonary edema 10.0
292 polyneuropathy 10.0
293 toxic shock syndrome 10.0
294 purpura 10.0
295 sheehan syndrome 10.0
296 dysphagia 10.0
297 hashimoto thyroiditis 10.0
298 pituitary hormone deficiency, combined, 2 10.0
299 rahman syndrome 10.0
300 myoglobinuria 10.0
301 thrombotic thrombocytopenic purpura 10.0
302 methemoglobinemia 10.0
303 hepatorenal syndrome 10.0
304 bronchopneumonia 10.0
305 dementia 10.0
306 acute cystitis 10.0
307 vascular disease 10.0
308 dental caries 10.0
309 substance abuse 10.0
310 paraplegia 10.0
311 inherited metabolic disorder 10.0
312 47,xyy 10.0
313 paracetamol poisoning 10.0
314 intussusception 9.9
315 sarcoidosis 1 9.9
316 thrombophilia due to thrombin defect 9.9
317 premature ovarian failure 7 9.9
318 migraine with aura 9.9
319 gastric ulcer 9.9
320 tetanus 9.9
321 goiter 9.9
322 basilar artery occlusion 9.9
323 beriberi 9.9
324 pericarditis 9.9
325 epilepsy 9.9
326 acromegaly 9.9
327 bilirubin metabolic disorder 9.9
328 pulmonary tuberculosis 9.9
329 anuria 9.9
330 ischemia 9.9
331 pituitary adenoma 9.9
332 chronic kidney disease 9.9
333 ileus 9.9
334 acute myocardial infarction 9.9
335 refractive error 9.9
336 central congenital hypothyroidism 9.9
337 fainting 9.9
338 hypertonia 9.9
339 ethylene glycol poisoning 9.9
340 pfeiffer syndrome 9.9
341 atrial standstill 1 9.9
342 diabetes insipidus, nephrogenic, autosomal 9.9
343 migraine, familial hemiplegic, 1 9.9
344 down syndrome 9.9
345 branchiootic syndrome 1 9.9
346 pulmonary disease, chronic obstructive 9.9
347 major affective disorder 8 9.9
348 major affective disorder 9 9.9
349 microvascular complications of diabetes 3 9.9
350 microvascular complications of diabetes 4 9.9
351 microvascular complications of diabetes 6 9.9
352 microvascular complications of diabetes 7 9.9
353 chorea, childhood-onset, with psychomotor retardation 9.9
354 joint laxity, short stature, and myopia 9.9
355 hirata disease 9.9
356 hyperphosphatemia 9.9
357 exanthem 9.9
358 atrioventricular block 9.9
359 sleep apnea 9.9
360 pain agnosia 9.9
361 ptosis 9.9
362 keratoconus 9.9
363 sarcoma 9.9
364 pituitary apoplexy 9.9
365 arteriovenous malformation 9.9
366 pyelonephritis 9.9
367 myopia 9.9
368 nephrotic syndrome 9.9
369 allergic hypersensitivity disease 9.9
370 neutropenia 9.9
371 graves' disease 9.9
372 potter's syndrome 9.9
373 choreatic disease 9.9
374 hyperparathyroidism 9.9
375 alcoholic liver cirrhosis 9.9
376 renal tubular acidosis 9.9
377 urticaria 9.9
378 hypogonadism 9.9
379 hyperinsulinism 9.9
380 benign mesothelioma 9.9
381 bipolar disorder 9.9
382 brain stem infarction 9.9
383 craniopharyngioma 9.9
384 intracranial thrombosis 9.9
385 spindle cell sarcoma 9.9
386 neurotic disorder 9.9
387 internuclear ophthalmoplegia 9.9
388 silent myocardial infarction 9.9
389 end stage renal disease 9.9
390 carotid artery occlusion 9.9
391 cataract 9.9
392 vasculitis 9.9
393 pulmonary embolism 9.9
394 sickle cell disease 9.9
395 cerebrospinal fluid leak 9.9
396 scleromyxedema 9.9
397 tuberculous meningitis 9.9
398 spinal cord injury 9.9
399 acyl-coa dehydrogenase deficiency 9.9
400 bickerstaff brainstem encephalitis 9.9
401 overgrowth syndrome 9.9
402 cardiac arrhythmia 9.8
403 multiple sclerosis 9.8
404 fibrosis of extraocular muscles, congenital, 1 9.8
405 renal cell carcinoma, nonpapillary 9.8
406 hypertriglyceridemia, familial 9.8
407 pheochromocytoma 9.8
408 porphyria, acute intermittent 9.8
409 schistosoma mansoni infection, susceptibility/ 9.8
410 afibrinogenemia, congenital 9.8
411 lung cancer 9.8
412 cystic fibrosis 9.8
413 galactorrhea 9.8
414 intracranial hypertension, idiopathic 9.8
415 pancreatic cancer 9.8
416 subacute sclerosing panencephalitis 9.8
417 sudden infant death syndrome 9.8
418 hypothyroidism, congenital, nongoitrous, 4 9.8
419 thyrotropin-releasing hormone deficiency 9.8
420 mycobacterium tuberculosis 1 9.8
421 leukemia, acute lymphoblastic 9.8
422 helix syndrome 9.8
423 gastrointestinal ulceration, recurrent, with dysfunctional platelets 9.8
424 foodborne botulism 9.8
425 vitamin b12 deficiency 9.8
426 oculogyric crisis 9.8
427 fibroma 9.8
428 adrenal gland pheochromocytoma 9.8
429 lymphoma 9.8
430 cerebral artery occlusion 9.8
431 mumps 9.8
432 glucose intolerance 9.8
433 rickets 9.8
434 dissociative disorder 9.8
435 asphyxia neonatorum 9.8
436 primary hyperparathyroidism 9.8
437 constrictive pericarditis 9.8
438 cardiac tamponade 9.8
439 paranoid schizophrenia 9.8
440 leukemia 9.8
441 von willebrand's disease 9.8
442 hemolytic-uremic syndrome 9.8
443 acute kidney tubular necrosis 9.8
444 pyloric stenosis 9.8
445 miller fisher syndrome 9.8
446 porphyria 9.8
447 klebsiella pneumonia 9.8
448 hyperinsulinemic hypoglycemia 9.8
449 schistosomiasis 9.8
450 plasmodium falciparum malaria 9.8
451 papilledema 9.8
452 personality disorder 9.8
453 normal pressure hydrocephalus 9.8
454 thrombocytopenia 9.8
455 duodenal ulcer 9.8
456 conversion disorder 9.8
457 islet cell tumor 9.8
458 constipation 9.8
459 transient cerebral ischemia 9.8
460 leptospirosis 9.8
461 psychotic disorder 9.8
462 dermatitis 9.8
463 glycogen storage disease 9.8
464 bruxism 9.8
465 euthyroid sick syndrome 9.8
466 glomerulonephritis 9.8
467 multiple endocrine neoplasia 9.8
468 tracheal stenosis 9.8
469 mood disorder 9.8
470 temporal lobe epilepsy 9.8
471 cellulitis 9.8
472 toxic encephalopathy 9.8
473 empty sella syndrome 9.8
474 thrombophlebitis 9.8
475 colonic pseudo-obstruction 9.8
476 movement disease 9.8
477 benign pleural mesothelioma 9.8
478 volkmann contracture 9.8
479 hemolytic anemia 9.8
480 compartment syndrome 9.8
481 muscular atrophy 9.8
482 neuroblastoma 9.8
483 peritonitis 9.8
484 measles 9.8
485 neuromyelitis optica 9.8
486 macroglobulinemia 9.8
487 exophthalmos 9.8
488 fatty liver disease 9.8
489 fasciitis 9.8
490 necrotizing fasciitis 9.8
491 diabetic neuropathy 9.8
492 lingual-facial-buccal dyskinesia 9.8
493 myotonic dystrophy 9.8
494 medium-chain acyl-coenzyme a dehydrogenase deficiency 9.8
495 2-methylacetoacetyl coa thiolase deficiency 9.8
496 adrenomyeloneuropathy 9.8
497 ciguatera fish poisoning 9.8
498 granulocytopenia 9.8
499 haemophilus influenzae 9.8
500 hashimoto encephalopathy 9.8
501 ogilvie syndrome 9.8
502 periodontal ehlers-danlos syndrome 9.8
503 secondary adrenal insufficiency 9.8
504 spinal shock 9.8
505 splenomegaly 9.8
506 opioid addiction 9.8
507 aneurysm 9.8
508 back pain 9.8
509 cerebral beriberi 9.8
510 familial or sporadic hemiplegic migraine 9.8
511 specific language disorder 9.8
512 serotonin syndrome 9.8
513 thyroid carcinoma 9.8
514 prune belly syndrome 9.6
515 neurofibromatosis, type ii 9.6
516 amyotrophic lateral sclerosis 1 9.6
517 arteries, anomalies of 9.6
518 episodic ataxia, type 2 9.6
519 autoimmune disease 9.6
520 burkitt lymphoma 9.6
521 breast cancer 9.6
522 hepatocellular carcinoma 9.6
523 candidiasis, familial, 1 9.6
524 carpal tunnel syndrome 9.6
525 coarctation of aorta 9.6
526 cryoglobulinemia, familial mixed 9.6
527 diabetes mellitus, noninsulin-dependent 9.6
528 discrimination, two-point, reduction in 9.6
529 dementia, lewy body 9.6
530 multiple endocrine neoplasia, type i 9.6
531 esophageal cancer 9.6
532 keloid formation 9.6
533 keratitis, hereditary 9.6
534 macroglossia 9.6
535 macular dystrophy, dominant cystoid 9.6
536 obsessive-compulsive disorder 9.6
537 oculopharyngeal muscular dystrophy 9.6
538 otitis media 9.6
539 pernicious anemia 9.6
540 pneumothorax, primary spontaneous 9.6
541 prader-willi syndrome 9.6
542 dowling-degos disease 1 9.6
543 scleroderma, familial progressive 9.6
544 spinocerebellar ataxia 6 9.6
545 sturge-weber syndrome 9.6
546 temporal arteritis 9.6
547 tetralogy of fallot 9.6
548 thyroid cancer, nonmedullary, 1 9.6
549 triiodothyronine receptor auxiliary protein 9.6
550 suppressor of tumorigenicity 3 9.6
551 vesicoureteral reflux 1 9.6
552 volvulus of midgut 9.6
553 acyl-coa dehydrogenase, very long-chain, deficiency of 9.6
554 anencephaly 9.6
555 celiac disease 1 9.6
556 cryptorchidism, unilateral or bilateral 9.6
557 cystinosis, nephropathic 9.6
558 cerebellar ataxia, mental retardation, and dysequilibrium syndrome 1 9.6
559 homocystinuria due to deficiency of n -methylenetetrahydrofolate reductase activity 9.6
560 hydroxykynureninuria 9.6
561 immune deficiency disease 9.6
562 leprosy 3 9.6
563 myasthenia gravis 9.6
564 myelofibrosis 9.6
565 3-methylglutaconic aciduria, type iii 9.6
566 orotic aciduria 9.6
567 5-oxoprolinase deficiency 9.6
568 peters-plus syndrome 9.6
569 body mass index quantitative trait locus 11 9.6
570 lesch-nyhan syndrome 9.6
571 hemophilia b 9.6
572 glycerol kinase deficiency 9.6
573 mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes 9.6
574 prostatic hyperplasia, benign 9.6
575 retinitis pigmentosa 14 9.6
576 frontotemporal dementia 9.6
577 asthma 9.6
578 dermatitis herpetiformis, familial 9.6
579 leukemia, acute myeloid 9.6
580 body mass index quantitative trait locus 9 9.6
581 migraine, familial hemiplegic, 2 9.6
582 homocysteinemia 9.6
583 body mass index quantitative trait locus 8 9.6
584 sickle cell anemia 9.6
585 ascaris lumbricoides infection 9.6
586 langerhans cell histiocytosis 9.6
587 3-hydroxy-3-methylglutaryl-coa synthase-2 deficiency 9.6
588 meningioma, radiation-induced 9.6
589 hurler syndrome 9.6
590 meningioma, familial 9.6
591 epilepsy, partial, with pericentral spikes 9.6
592 coronary heart disease 1 9.6
593 body mass index quantitative trait locus 4 9.6
594 body mass index quantitative trait locus 10 9.6
595 body mass index quantitative trait locus 7 9.6
596 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 9.6
597 hyperinsulinemic hypoglycemia, familial, 5 9.6
598 hyperinsulinemic hypoglycemia, familial, 4 9.6
599 intraocular pressure quantitative trait locus 9.6
600 body mass index quantitative trait locus 12 9.6
601 acute promyelocytic leukemia 9.6
602 body mass index quantitative trait locus 14 9.6
603 fatty liver disease, nonalcoholic 1 9.6
604 gastric cancer 9.6
605 aspergillosis 9.6
606 glutathione peroxidase deficiency 9.6
607 leptin deficiency or dysfunction 9.6
608 retinal dystrophy, iris coloboma, and comedogenic acne syndrome 9.6
609 mandibular hypoplasia, deafness, progeroid features, and lipodystrophy syndrome 9.6
610 body mass index quantitative trait locus 18 9.6
611 leukemia, acute lymphoblastic 3 9.6
612 pachyonychia congenita 3 9.6
613 striatal degeneration, autosomal dominant 2 9.6
614 hydrops, lactic acidosis, and sideroblastic anemia 9.6
615 global developmental delay, absent or hypoplastic corpus callosum, and dysmorphic facies 9.6
616 hyperlipoproteinemia, type iii 9.6
617 body mass index quantitative trait locus 19 9.6
618 body mass index quantitative trait locus 20 9.6
619 lipoprotein quantitative trait locus 9.6
620 angina pectoris 9.6
621 pulmonary hypertension 9.6
622 tick-borne encephalitis 9.6
623 korean hemorrhagic fever 9.6
624 congenital hypothyroidism 9.6
625 epidemic typhus 9.6
626 intestinal schistosomiasis 9.6
627 small cell carcinoma 9.6
628 mantle cell lymphoma 9.6
629 paraganglioma 9.6
630 second-degree atrioventricular block 9.6
631 adrenal cortical adenoma 9.6
632 infective endocarditis 9.6
633 withdrawal disorder 9.6
634 anosognosia 9.6
635 organic acidemia 9.6
636 tracheomalacia 9.6
637 cryptococcal meningitis 9.6
638 meningococcal meningitis 9.6
639 polycystic kidney disease 9.6
640 asymptomatic neurosyphilis 9.6
641 cysticercosis 9.6
642 dermatomyositis 9.6
643 brown's tendon sheath syndrome 9.6
644 exhibitionism 9.6
645 thalassemia 9.6
646 parotitis 9.6
647 viral meningitis 9.6
648 endocarditis 9.6
649 bacterial infectious disease 9.6
650 legionellosis 9.6
651 common cold 9.6
652 leukodystrophy 9.6
653 interstitial nephritis 9.6
654 cystinosis 9.6
655 chronic pyelonephritis 9.6
656 malignant hypertension 9.6
657 meningocele 9.6
658 corneal edema 9.6
659 placenta praevia 9.6
660 prostatic hypertrophy 9.6
661 hantavirus hemorrhagic fever with renal syndrome 9.6
662 spinal meningioma 9.6
663 horner's syndrome 9.6
664 mitral valve insufficiency 9.6
665 suppurative otitis media 9.6
666 oculomotor nerve paralysis 9.6
667 gestational diabetes 9.6
668 lyme disease 9.6
669 esophagitis 9.6
670 low compliance bladder 9.6
671 aseptic meningitis 9.6
672 dengue disease 9.6
673 male infertility 9.6
674 alcoholic hepatitis 9.6
675 blood coagulation disease 9.6
676 chronic progressive external ophthalmoplegia 9.6
677 acute leukemia 9.6
678 blastomycosis 9.6
679 nephrocalcinosis 9.6
680 ocular motility disease 9.6
681 guillain-barre syndrome 9.6
682 hypochondriasis 9.6
683 vertebrobasilar insufficiency 9.6
684 severe pre-eclampsia 9.6
685 hellp syndrome 9.6
686 gout 9.6
687 nodular goiter 9.6
688 typhoid fever 9.6
689 scrub typhus 9.6
690 neurosarcoidosis 9.6
691 pulmonary sarcoidosis 9.6
692 obstructive jaundice 9.6
693 patent foramen ovale 9.6
694 sick sinus syndrome 9.6
695 autoimmune polyendocrine syndrome 9.6
696 obstructive hydrocephalus 9.6
697 central neurocytoma 9.6
698 chronic purulent otitis media 9.6
699 oral candidiasis 9.6
700 candidiasis 9.6
701 avoidant personality disorder 9.6
702 angioedema 9.6
703 mental depression 9.6
704 benign breast phyllodes tumor 9.6
705 pneumothorax 9.6
706 neovascular glaucoma 9.6
707 factitious disorder 9.6
708 hepatitis c 9.6
709 malignant fibrous histiocytoma 9.6
710 cholecystitis 9.6
711 rectum cancer 9.6
712 encephalomalacia 9.6
713 autoimmune hepatitis 9.6
714 post-traumatic stress disorder 9.6
715 intestinal perforation 9.6
716 lateral sclerosis 9.6
717 gastroenteritis 9.6
718 motor peripheral neuropathy 9.6
719 kluver-bucy syndrome 9.6
720 hemangioma 9.6
721 dysembryoplastic neuroepithelial tumor 9.6
722 myoma 9.6
723 contact dermatitis 9.6
724 melancholia 9.6
725 hemoglobin c disease 9.6
726 hemoglobinopathy 9.6
727 prostatic adenoma 9.6
728 cryoglobulinemia 9.6
729 cystic kidney disease 9.6
730 breast malignant phyllodes tumor 9.6
731 early myoclonic encephalopathy 9.6
732 ascaridiasis 9.6
733 cystadenocarcinoma 9.6
734 gallbladder cancer 9.6
735 neurilemmoma 9.6
736 demyelinating disease 9.6
737 myelitis 9.6
738 aspiration pneumonitis 9.6
739 central nervous system disease 9.6
740 mesenchymal cell neoplasm 9.6
741 palmoplantar keratosis 9.6
742 inappropriate adh syndrome 9.6
743 histiocytosis 9.6
744 cerebritis 9.6
745 mammary paget's disease 9.6
746 cavernous sinus thrombosis 9.6
747 sagittal sinus thrombosis 9.6
748 mucinous cystadenocarcinoma 9.6
749 aortic aneurysm 9.6
750 intermittent claudication 9.6
751 skin disease 9.6
752 ovary adenocarcinoma 9.6
753 pleural empyema 9.6
754 gastritis 9.6
755 tricuspid valve insufficiency 9.6
756 brain stem cancer 9.6
757 radiculopathy 9.6
758 fibrous histiocytoma 9.6
759 bartter disease 9.6
760 avian influenza 9.6
761 large cell carcinoma 9.6
762 subacute bacterial endocarditis 9.6
763 secretory meningioma 9.6
764 lymphoplasmacyte-rich meningioma 9.6
765 subacute glomerulonephritis 9.6
766 lymph node tuberculosis 9.6
767 bronchiolo-alveolar adenocarcinoma 9.6
768 thyroid gland disease 9.6
769 middle ear disease 9.6
770 ovarian cyst 9.6
771 ureteral obstruction 9.6
772 urinary tract obstruction 9.6
773 infertility 9.6
774 intestinal disease 9.6
775 lung oat cell carcinoma 9.6
776 t-cell acute lymphoblastic leukemia 9.6
777 third cranial nerve disease 9.6
778 acute stress disorder 9.6
779 lymphopenia 9.6
780 acquired immunodeficiency syndrome 9.6
781 juvenile rheumatoid arthritis 9.6
782 mitochondrial myopathy 9.6
783 active peptic ulcer disease 9.6
784 parathyroid adenoma 9.6
785 mediastinitis 9.6
786 myocarditis 9.6
787 intestinal obstruction 9.6
788 arthritis 9.6
789 lung disease 9.6
790 dermatitis herpetiformis 9.6
791 collagen disease 9.6
792 malignant hyperthermia 9.6
793 herpes simplex 9.6
794 ulcerative colitis 9.6
795 scarlet fever 9.6
796 chickenpox 9.6
797 bacterial pneumonia 9.6
798 lupus erythematosus 9.6
799 autosomal dominant polycystic kidney disease 9.6
800 peliosis hepatis 9.6
801 gas gangrene 9.6
802 tracheitis 9.6
803 hypertensive encephalopathy 9.6
804 cholangitis 9.6
805 pulmonary emphysema 9.6
806 yellow fever 9.6
807 alopecia 9.6
808 muscular dystrophy 9.6
809 mixed phenotype acute leukemia 9.6
810 toxoplasmosis 9.6
811 hypereosinophilic syndrome 9.6
812 keloid disorder 9.6
813 acute myeloblastic leukemia with maturation 9.6
814 antisynthetase syndrome 9.6
815 chromosome 1q deletion 9.6
816 dipsogenic diabetes insipidus 9.6
817 exfoliative dermatitis 9.6
818 fasting hypoglycemia 9.6
819 hansen's disease 9.6
820 hemorrhagic proctocolitis 9.6
821 herpes simplex encephalitis 9.6
822 limbic encephalitis 9.6
823 mallory-weiss syndrome 9.6
824 migraine with brainstem aura 9.6
825 mitochondrial encephalomyopathy lactic acidosis and stroke-like episodes 9.6
826 neurosyphilis 9.6
827 papular mucinosis 9.6
828 pontine hemorrhage 9.6
829 post-traumatic epilepsy 9.6
830 spastic paraparesis 9.6
831 weber syndrome 9.6
832 depression 9.6
833 autonomic dysfunction 9.6
834 cerebral aneurysms 9.6
835 chronic pain 9.6
836 dysautonomia 9.6
837 febrile seizures 9.6
838 hypersomnia 9.6
839 myotonia 9.6
840 paroxysmal choreoathetosis 9.6
841 pituitary tumors 9.6
842 postherpetic neuralgia 9.6
843 posttransplant acute limbic encephalitis 9.6
844 rapidly involuting congenital hemangioma 9.6
845 acute sensory ataxic neuropathy 9.6
846 acute encephalopathy with biphasic seizures and late reduced diffusion 9.6
847 acquired methemoglobinemia 9.6
848 zinc-responsive necrolytic acral erythema 9.6
849 methanol poisoning 9.6
850 benign idiopathic neonatal seizures 9.6
851 pneumococcal meningitis 9.6
852 disorder of energy metabolism 9.6
853 infectious encephalitis 9.6
854 acute adrenal insufficiency 9.6
855 thrombotic microangiopathy 9.6
856 primary adrenal insufficiency 9.6

Comorbidity relations with Ocular Motor Apraxia via Phenotypic Disease Network (PDN): (showing 16, show less)


Active Peptic Ulcer Disease Acute Cystitis
Acute Kidney Failure Alzheimer Disease
Cardiac Arrest Decubitus Ulcer
Deficiency Anemia Epilepsy, Focal, with Speech Disorder and with or Without Mental Retardation
Familial Atrial Fibrillation Heart Disease
Hypertension, Essential Protein-Energy Malnutrition
Respiratory Failure Schizophreniform Disorder
Swallowing Disorders Ventricular Fibrillation, Paroxysmal Familial, 1

Graphical network of the top 20 diseases related to Ocular Motor Apraxia:



Diseases related to Ocular Motor Apraxia

Symptoms & Phenotypes for Ocular Motor Apraxia

Human phenotypes related to Ocular Motor Apraxia:

31 (showing 4, show less)
# Description HPO Frequency HPO Source Accession
1 nephronophthisis 31 HP:0000090
2 oculomotor apraxia 31 HP:0000657
3 jerky head movements 31 HP:0006961
4 horizontal opticokinetic nystagmus 31 HP:0008026

Symptoms via clinical synopsis from OMIM:

56
Head And Neck Head:
jerking head movements

Head And Neck Eyes:
oculomotor apraxia (defective/absent horizontal eye movements)

Neurologic Central Nervous System:
jerking head movements

Clinical features from OMIM:

257550

UMLS symptoms related to Ocular Motor Apraxia:


seizures, tremor, back pain, headache, ophthalmoparesis, lethargy, syncope, excessive daytime somnolence, pain, chronic pain, sciatica, vertigo/dizziness, sleeplessness, symptoms, central nervous system signs and symptoms, clouded consciousness, sluggishness, dizziness, transient alteration of awareness, other alteration of consciousness

Drugs & Therapeutics for Ocular Motor Apraxia

Drugs for Ocular Motor Apraxia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 384, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Clavulanate Approved, Vet_approved Phase 4 58001-44-8 5280980
2
Dobutamine Approved Phase 4 34368-04-2 36811
3
Clopidogrel Approved Phase 4 113665-84-2, 120202-66-6 60606
4
Haloperidol Approved Phase 4 52-86-8 3559
5
Chlorhexidine Approved, Vet_approved Phase 4 55-56-1 9552079 2713
6
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 119141-88-7, 161973-10-0 9568614 4594
7
Histamine Approved, Investigational Phase 4 51-45-6 774
8
Famotidine Approved Phase 4 76824-35-6 3325
9
Zinc Approved, Investigational Phase 4 7440-66-6 32051
10
Glimepiride Approved Phase 4 93479-97-1 3476
11
Vildagliptin Approved, Investigational Phase 4 274901-16-5 6918537
12
Insulin glargine Approved Phase 4 160337-95-1
13
Isoflurane Approved, Vet_approved Phase 4 26675-46-7 3763
14
Abciximab Approved Phase 4 143653-53-6
15
Tirofiban Approved Phase 4 144494-65-5 60947
16
Gliclazide Approved Phase 4 21187-98-4 3475
17
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
18
Diethylcarbamazine Approved, Investigational, Vet_approved Phase 4 90-89-1 3052
19
Ivermectin Approved, Investigational, Vet_approved Phase 4 70288-86-7 6474909
20
Ticagrelor Approved Phase 4 274693-27-5 9871419
21
Cangrelor Approved Phase 4 163706-06-7 9854012
22
Rifaximin Approved, Investigational Phase 4 80621-81-4 6436173 46783403
23
Lactulose Approved Phase 4 4618-18-2 11333
24
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 5311068 68602
25
Ferrous fumarate Approved Phase 4 141-01-5
26
Iron Approved, Experimental Phase 4 15438-31-0, 7439-89-6 27284 23925
27
Amantadine Approved Phase 4 768-94-5 2130
28
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
29
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
30
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
31
tannic acid Approved Phase 4 1401-55-4
32
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
33
Acetaminophen Approved Phase 4 103-90-2 1983
34
Conivaptan Approved, Investigational Phase 4 210101-16-9 151171
35
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
36
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
37
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
38
Tolvaptan Approved Phase 4 150683-30-0 216237
39
Phenylalanine Approved, Investigational, Nutraceutical Phase 4 63-91-2 6140
40
Ornithine Approved, Nutraceutical Phase 4 70-26-8, 3184-13-2 6262
41
Thiamine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 59-43-8, 70-16-6 1130
42
Aspartic acid Approved, Nutraceutical Phase 4 56-84-8 5960
43
Melatonin Approved, Nutraceutical, Vet_approved Phase 4 73-31-4 896
44 Amoxicillin-Potassium Clavulanate Combination Phase 4
45 Antipsychotic Agents Phase 4
46 Anesthetics, Inhalation Phase 4
47 Dopamine Antagonists Phase 4
48 Haloperidol decanoate Phase 4
49 Chlorhexidine gluconate Phase 4
50 Thiamin Phase 4
51 glutamine Phase 4
52 Histamine Antagonists Phase 4
53 Histamine H2 Antagonists Phase 4
54
Histamine Phosphate Phase 4 51-74-1 65513
55 Proton Pump Inhibitors Phase 4
56 Dipeptidyl-Peptidase IV Inhibitors Phase 4
57 Immunologic Factors Phase 4
58 Antiparasitic Agents Phase 4
59 N-Methylaspartate Phase 4
60 Anthelmintics Phase 4
61 Dermatologic Agents Phase 4
62 Anti-Infective Agents, Local Phase 4
63 Disinfectants Phase 4
64 Trace Elements Phase 4
65 Nutrients Phase 4
66 Micronutrients Phase 4
67 Gastrointestinal Agents Phase 4
68 Purinergic P2Y Receptor Antagonists Phase 4
69 Adrenergic alpha-Agonists Phase 4
70 Adrenergic Agents Phase 4
71 Adrenergic Agonists Phase 4
72 Laxatives Phase 4
73 Cathartics Phase 4
74 Polyethylene glycol 3350 Phase 4
75 Prasugrel hydrochloride Phase 4 389574-19-0
76 Antiparkinson Agents Phase 4
77 Cerebrolysin Phase 4
78 Neuroprotective Agents Phase 4
79 Hypnotics and Sedatives Phase 4
80 Anti-Anxiety Agents Phase 4
81 Psychotropic Drugs Phase 4
82 GABA Modulators Phase 4
83 Antiemetics Phase 4
84 Neuromuscular Blocking Agents Phase 4
85 Insulin, Globin Zinc Phase 4
86 Hypoglycemic Agents Phase 4
87 insulin Phase 4
88 Hormone Antagonists Phase 4
89 Antidotes Phase 4
90 Protective Agents Phase 4
91 Liver Extracts Phase 4
92 Antioxidants Phase 4
93 Respiratory System Agents Phase 4
94 Vasopressins Phase 4
95 Arginine Vasopressin Phase 4
96 Antineoplastic Agents, Hormonal Phase 4
97 glucocorticoids Phase 4
98 BB 1101 Phase 4
99 Expectorants Phase 4
100 N-monoacetylcystine Phase 4
101
L-Alanine Nutraceutical Phase 4 56-41-7 5950
102
Nitazoxanide Approved, Investigational, Vet_approved Phase 2, Phase 3 55981-09-4 41684
103
Quinine Approved Phase 2, Phase 3 130-95-0 8549 3034034